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Lipids and cardiovascular disease: where 
does dietary intervention sit alongside 
statin therapy?  
Ian L Megson
a
, Phillip D Whitfield
a
 and Ioannis Zabetakis
b 
The Seven Countries Study suggested an association 
between serum cholesterol and cardiovascular disease 
(CVD). However, the association was not consistent across 
the various cohorts of participants in different countries; 
while it was very clear in US and Northern European cohorts, 
it was weak in Southern European and Japanese cohorts. 
Nevertheless, the study triggered research into cholesterol-
lowering drug strategies, ultimately leading to the 
development of statins amongst others. Clinical evidence in 
support of statins is strong and the vast majority of the 
medical community advocate these drugs as highly effective 
first-line therapeutics in primary and secondary prevention 
of CVD. However, growing evidence of side-effects 
associated with statins in a significant proportion of patients 
suggests that these drugs are not a universal solution to CVD. 
There is a need, therefore, to revisit the evidence and to re-
appraise the relative importance of cholesterol amongst 
many other lipids as potential modulators of atherogenesis. 
In this review, we assess the relative merits of statin therapy 
in CVD versus dietary interventions that impact on lipids 
other than cholesterol, including omega-3 fatty acids and 
polar lipid fractions of various foods (e.g. fish and olive oil). 
We conclude that careful design around the lipid 
components of dietary interventions presents a credible 
alternative in patients who are intolerant to statins or averse 
to taking such drugs. 
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Introduction  
Cardiovascular Disease 
Atherosclerosis is the complex process (Figure 1) that 
underpins the clinically relevant manifestations of 
cardiovascular disease, including ischaemic stroke, myocardial 
infarction and peripheral vascular disease. It has long been 
recognised that atheroma in humans is composed primarily of 
lipid.
1
 Atherosclerosis involves the accumulation of 
cholesterol, cholesterol esters, triglycerides and 
phospholipids
2
 in conduit arterial walls, initially forming fatty 
streaks and progressing to complex atherosclerotic plaques 
that partially occlude the lumen of the vessel and restrict 
blood flow. Plaque development often resolves to leave a lipid-
rich protuberance in the vessel wall, overlain by smooth 
muscle and devoid of ongoing inflammation.
3
 These “stable” 
plaques tend not to present a threat to life, although they can 
cause debilitating symptoms if they cause a substantial 
reduction in blood flow. A minority of plaques, however, 
persist in a complex, unstable state which is prone to erosion 
and/or rupture.
4, 5
 Plaque rupture exposes the pro-thrombotic 
core of the plaque to the blood and results in the rapid 
development of a thrombus in situ,
6
 which can occlude the 
artery and result in a myocardial infarction or ischaemic 
stroke, depending on the location of the thrombus. 
 
Figure 1 
 
Evidence for the lipid hypothesis 
 
Several population-based studies were conducted in the mid-
to-late twentieth century, the findings of which supported an 
association between blood-borne cholesterol (serum total 
cholesterol) and cardiovascular risk.
7, 8
 The so-called “lipid 
hypothesis” was proposed in the late 1970s, stating that 
lowering blood cholesterol would be an effective means of 
reducing cardiovascular risk.
9
 The lipid hypothesis is widely 
accepted amongst the medical community,
10, 11
 but is still hotly 
disputed by a minority on the grounds of flawed methodology 
and publication bias.
12-16
  
Part of the problem with the lipid hypothesis is that, in light of 
more recently accumulated knowledge of atherosclerosis, it is 
over-simplistic, both in its definition of “lipid” and in its 
interpretation of the role of lipids in the atherogenic process. 
In the context of the lipid hypothesis, “lipid” really refers to 
“total serum cholesterol”, to the exclusion of other important 
lipid classes and with little consideration of the blood-borne 
lipid transport particles (chylomicrons, VLDL, LDL, IDL and 
HDL). In addition, lipid accumulation in the vessel wall is an 
inflammatory process
17
 with a requirement for oxidative 
modification of cholesterol to progress.
18, 19
 Targeted anti-
inflammatory agents and antioxidants might, therefore, have 
as much of a therapeutic role to play as cholesterol lowering in 
slowing the disease process. Indeed, given our current 
understanding of the principal role played by inflammation in 
plaque stability,
20
 selective anti-inflammatory agents might 
represent the best target for preventing plaque rupture, 
although no anti-inflammatory interventions have yet shown 
clinical benefit in this setting. 
 
 
Pharmaceutical Interventions for CVD 
The high incidence and mortality associated with 
atherosclerosis makes it a major target for pharmaceutical 
intervention. The complex nature of the disease promotes a 
number of potential drug targets, from oxidative stress to 
inflammation, thrombosis and lipid lowering.  By far the most 
successful target to date has been lowering of circulating 
cholesterol. Statins are by far the best known and most 
frequently used drugs to lower cholesterol and, as such, are 
the focus of this review. However, it is important to note that 
other cholesterol-lowering strategies have emerged with 
alternative mechanisms to reduce cholesterol, most notably 
inhibitors of dietary cholesterol absorption (stanols, sterols
21, 
22
 and the drug ezetimide
23, 24
), and proprotein convertase 
subtilisin/kexin type 9 serine protease (PCSK9) inhibitors, 
which are now approved to be used as adjuvants to statins in 
high risk patients (e.g. with familial hypercholesterolaemia) by 
modulating LDL receptor degradation.
25, 26
  
.  
 
Cholesterol-lowering by statins 
Besides dietary intervention studies, the other major 
consequence of the Seven Countries Study was the triggering 
of pharmaceutical Industry interest in therapeutic 
interventions to lower cholesterol. Notwithstanding the 
controversy around the lipid hypothesis, cholesterol–lowering 
was considered to be a therapeutic target worth exploring. At 
the outset, it was recognised that the major determinant of 
blood-borne cholesterol was de novo synthesis in the liver; 
dietary intake is a secondary, but nevertheless modifiable, 
contributor. 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) 
reductase is known to be the rate-limiting step in the synthetic 
pathway and was first targeted in the 1970s.
27
 The 
pharmaceutical promise of this approach was quickly 
recognised, leading to the development of the first 
commercially available statin, lovastatin. Since then, a range of 
statins have been developed by different pharmaceutical 
companies, each with subtle differences in terms of benefits 
and side-effect profile.
28
 
 
Biochemistry 
While the concept of inhibiting the rate-limiting enzyme 
involved in hepatic cholesterol synthesis is straightforward, the 
means by which the inhibition effects reduced cholesterol 
levels in the blood is more complex than might have been 
envisaged at the outset (Figure 2). Certainly, the reduced 
synthesis manifests in a reduction in export of cholesterol from 
hepatocytes in the form of VLDL. However, low intracellular 
concentrations of cholesterol also induce an adaptive response 
whereby expression of LDL receptors (LDL-Rs) is enhanced to 
increase sequestration of cholesterol-laden LDL from the 
blood,
29
 presumably in order to maintain intracellular 
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cholesterol stocks. In addition, it appears that statins have a 
significant impact on high density lipoprotein (HDL),
30, 31
 which 
could contribute to the anti-atherogenic effects of statins by 
increasing so-called reverse cholesterol transport - out of LDL-
engorged macrophages (foam cells) and back to the liver. 
Evidence relating to atorvastatin suggests that the mechanism 
underpinning this effect might be enhanced Apo-A1 
production and subsequent elevation of the plasma HDL 
pool.
32
 Disentangling the relative benefits of increased plasma 
HDL vs. reduced plasma LDL is all but impossible, but it is 
widely accepted that the dramatic improvement in HDL:LDL 
ratio is the principal driver for improved outcome associated 
with statins in patients with cardiovascular disease. 
 
Figure 2 
 
 
Pleiotropic effects 
Another unforeseen benefit of statins is that they might confer 
benefit through mechanisms not associated with cholesterol 
trafficking – so-called pleiotropic effects.
33
 Interestingly, many 
of the pleiotropic effects described to date relate to protection 
against endothelial dysfunction, thrombosis, inhibition of 
inflammation
34-36
 and/or oxidative stress,
37, 38
 suggesting that 
statins might strike at all of the key processes involved in 
atherogenesis (Figure 2), often through mechanisms not 
directly mediated by cholesterol.
39
 Amongst the most 
convincing of the pleiotropic effects described to date are anti-
inflammatory and antioxidant effects. 
37, 38
   
 
Clinical Evidence: Benefits of Statins in cardiovascular disease 
Over the past 25 years, a number of clinical studies have been 
conducted to assess the ability of statins to reduce 
cardiovascular risk. A meta-analysis of 14 randomised trials 
(90,056 patients) found that statins effectively reduced the risk 
of major vascular events (fatal and non-fatal) by ~20% per mM 
of LDL cholesterol reduction. This translated into 4.8% fewer 
vascular events in patients with pre-existing CHD and 2.5% in 
those without a history of CHD.
40
 A meta-analysis of intensive 
lipid-lowering concurred with ~20% reduction per mM LDL 
cholesterol lowering and concluded that lowering cholesterol 
by 2-3 mM could reduce risk by 40-50%.
41
 The Cochrane 
Review of eighteen randomised control trials (56,934 
participants) found a combined fatal and non-fatal CVD 
relative risk of 0.75 (95% CI 0.70 to 0.81), combined fatal and 
non-fatal CHD events relative risk of 0.73 (95% CI 0.67 to 0.80) 
and combined fatal and non-fatal stroke relative risk of 0.78 
(95% CI 0.68 to 0.89).
42 A separate systematic review 
compared studies with three different statins (atorvastatin, 
pravastatin and simvastatin) and found there to be no 
significant difference between them in terms of risk 
reduction.
43
 The latest finding relates back to one of the 
earliest statin trials - the West of Scotland Coronary Prevention 
Study (WOSCOPS) - which shows a legacy benefit of statin 
treatment at 15 years after the 5 year study, amounting to a 
21% reduction in cardiovascular mortality.
44
 Indeed, the effect 
of statins is sufficiently powerful to skew the findings of 
contemporary observational studies.
45
 
 
On the face of it, these data are incontrovertible: statins 
reduce cardiovascular risk and the more intensive the better. 
However, there remains a surprisingly vociferous lobby, 
including clinicians, scientists and patients, which is 
vehemently against widespread statin use.
46
 While some of 
the scepticism might hark back to perceived flaws in the 
original lipid hypothesis and the early epidemiological data, 
some reflects genuine concerns about study design, reporting 
bias and underestimation of side effects. 
 
 
Side effects 
The HMG-CoA pathway is not only responsible for cholesterol 
synthesis, but also several other cellular processes, including 
prenylation (linking of lipid moieties to aid association with cell 
membranes) of specific proteins. Inhibition of this process is 
believed to have both beneficial and detrimental effects: many 
of the pleiotropic effects of statins are attributed, at least in 
part, to inhibition of prenylation, as are some of the reductions 
in cancer risk. However, inhibition of prenylation has also been 
implicated in some of the adverse effects of statins. 
 
Meta-analyses have found no evidence to suggest that statins 
have any adverse impact on cancer incidence; indeed statins 
may even reduce the risk of certain cancers (oesophageal, 
colo-rectal, gastric and prostate). However, statins are known 
to increase the risk of liver damage,
47
 and, ironically, to 
increase risk of type 2 diabetes,
47, 48
 one of the major risk 
factors for cardiovascular-related deaths. The headline figure 
for increased risk of type 2 diabetes amongst patients on 
statins in the METSIM trial was 46%, with a 24% decrease in 
insulin sensitivity and 12% reduction in insulin secretion.
48
 
Importantly, for two of the most prescribed statins, 
simvastatin and atorvastatin, the effect was dose-dependent, 
which presents a counter-argument to using increased statin 
doses to keep LDL cholesterol levels as low as possible. Mild 
cognitive impairment, neuropathy and sexual dysfunction are 
also weakly associated with statin use. 
 
Perhaps the most commonly reported side-effect of statins (in 
up to 15% of patients receiving statins), however, relate to 
muscle damage and pain (myopathy and myalgia).
49, 50
 Whilst 
not life-threatening, these effects can be debilitating and have 
a substantial impact on quality of life and, in some cases, result 
in long-term muscle damage. It is these side-effects that are 
primarily responsible for patient intolerance and non-
compliance to statin therapies and should not be 
underestimated.  
 
Lipid-based dietary Interventions for CVD 
Given the importance of a range of lipids at different points in the 
atherosclerotic process, it is unsurprising that dietary interventions 
have long been advocated as a potential preventative measure or 
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intervention in CVD. The most obvious such intervention is low fat 
and low cholesterol diets and ingredients, but for the purposes of 
this review we will concentrate on supplementation of lipid 
moieties that are considered to be beneficial in the CVD setting. 
 
Omega-3 polyunsaturated fatty acids 
The emphasis from the lipid hypothesis-driven research was 
centred on lipids (or more accurately, cholesterol) being 
harmful, but at the same time, there was significant evidence 
building to suggest that another class of lipids, Omega-3 
polyunsaturated fatty acids, might actually be beneficial. 
Epidemiological studies indicated that certain populations and 
cultures (e.g. Netherlands, 
51
 Finland, Mediterranean, 
Greenland Inuit and Danes, 
52
 Japan
8
) have notably lower 
incidence of CVD than others. A common feature of the diet 
amongst these populations is a relatively high dietary intake of 
fish. Irrespective of the many shortcomings (highlighted in 
53
) 
of the research that identified fish 
54
 as one of several 
mediators of the effects seen, the association between fish, 
and oily fish in particular, with cardiovascular disease is upheld 
in meta-analyses 
55-57
 and has fuelled a huge research interest 
in the concept that eating fish might hold health benefits. 
There is now substantial evidence to support the benefits of 
dietary consumption of fish, particularly oily varieties such as 
salmon, trout, sardines, mackerel and herring, to help combat 
cardiovascular disease. The paradigm for the beneficial effects 
relating to these fish is that they are high in polyunsaturated 
fatty acids (PUFAs) and omega-3 fatty acids in particular. 
Although the merits of omega-3 fatty acids are sometimes tied 
to their antioxidant activity, it is clear that their activity is 
complex and multi-factorial. An important mode of action is 
via provision of substrate for synthesis of inflammation-
resolving eicosanoids (resolvins, protectins and maresins), but 
they are also recognised to reduce triglyceride levels 
58
, to 
have anti-thrombotic effects, increase membrane fluidity and 
to induce plaque stability; many of these effects are less well 
understood. In the wake of early highly-publicised findings, 
health providers in many countries issued guidelines in 
support of eating oily fish and/or taking omega-3 supplements. 
However, once blinded studies were conducted in patient 
groups with already optimised conventional therapy (e.g. 
statins), much of the euphoria subsided and some health 
authorities  retracted their advice on pure omega-3 
supplements, but maintained their support for eating oily fish. 
Based on the current evidence, the National Institute for 
Health & Care Excellence guidelines in UK recommends:  
“that people at high risk of, or with, cardiovascular disease 
should be advised to consume at least two portions of fish per 
week, including a portion of oily fish. However it advises that 
omega-3 fatty acid compounds should not be offered for the 
prevention of cardiovascular disease to people who are being 
treated for primary or secondary prevention of cardiovascular 
disease, alone or in combination with a statin, including in 
people with chronic kidney disease or type 1 or type 2 
diabetes.”  
Omega 3 is not licensed for use post-myocardial infarction (MI) 
in the USA, but the American Heart Association does 
recommend the use of oily fish or omega-3 capsules post-MI 
59
. Meanwhile, the European Cardiology Society notes the lack 
of evidence to support omega-3 use in secondary prevention 
(e.g. post-MI), but advocates its use in reducing triglycerides as 
an adjunct to statins 
60
. 
The dichotomy in advice between whole oily fish and omega-3 
products is striking and suggests that there is a sense in the 
clinical community that omega-3 is not yet sufficiently proven 
to justify the costs of prescription – advising people to eat oily 
fish does not carry the same cost to healthcare providers and, 
arguably, is supported by better evidence. 
Despite the discrepancy between findings from whole fish or 
whole fish oil and those from pure omega-3s, little attention 
has been given to understanding the dichotomy. One obvious 
explanation is that whole fish/whole fish oil is a complex 
mixture of lipids, only a small component of which is omega-3. 
There is potential, therefore, for other lipids in the mixture to 
be beneficial, either in an additive or even a synergistic way. 
 
Fish/fish oil/omega-3 consumption and cardiovascular disease 
(coronary artery disease and its consequences) 
By way of a very brief review of the clinical studies relating to 
oily fish and omega-3 capsules, the clinical data can be broadly 
divided into population-based studies and randomized control 
trials. 
 
Population-based studies 
Numerous population-based studies have been conducted 
over the past 40 years to establish an association between 
fish-eating dietary habits and risk of coronary artery disease 
and cardiovascular-related sudden death. As always, given the 
heterogeneity of the studies conducted, with different end-
points, populations, average fish consumption and type of fish 
consumed, it is difficult to reach firm conclusions regarding the 
association, but meta-analyses of these studies would suggest 
that there is an association between fish consumption and risk 
of coronary artery disease and myocardial infarction (MI). 
There is always a danger, however, of over-interpreting an 
association as a causal relationship, so these findings should 
really only be seen as a fore-runner for randomised controlled 
trials to test the hypothesis robustly. 
 
Randomized trials 
A wide range of trials have reported on the impact of fish, fish 
oils and omega-3 capsules on risk of cardiovascular disease. 
The first two trials of this kind were GISSI-P (1999)
61
 and JELIS 
(2007);
62
 a significant relative risk reduction (~20-35% 
depending on outcome measure) was found for both trials but, 
importantly, these were open-label trials and did not have a 
placebo control arm. Four further trials reported in 2007 
(GISSI-HF)
63
 and 2010 (Alpha Omega,
64
 Omega
65
 and 
SU.FOL.OM3
66
). GISSI-HF found a modest but significant 
benefit of omega-3 (~8-10% risk reduction), whereas none of 
the three other trials showed any benefit. The reason for the 
difference in the outcome of GISSI-HF is not easy to identify, 
but it might be important that the target patient group was 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5  
Please do not adjust margins 
Please do not adjust margins 
heart failure, rather than CAD or post-MI, as for the other 3 
trials. These trials are summarised in Table 1. It is important to 
highlight, here, the fact that the placebo used in the Omega 
study was olive oil. Given the strong antioxidant and anti-
inflammatory activities of olive oil, choosing this placebo is a 
true limitation of the Omega study. 
 
Fish/fish oil/omega-3 consumption and blood pressure 
A few early studies investigated the impact of fish vs red meat 
on blood pressure, with mixed results. A number of studies 
have investigated the impact of fish oil supplements on blood 
pressure in both patients with hypertension (therapeutic) or 
normotensive people (preventative). Interestingly, 
supplementation in these studies is generally quantified in 
terms of EPA+DHA – indicative of the importance assigned to 
omega-3s in these studies. Meta-analyses of the best designed 
studies indicate a modest (~2 mm Hg) fall in blood pressure 
amongst patients, but little or no effect in normotensive 
individuals (which is not necessarily a bad thing).
67, 68
 There 
was no correlation between supplement fish oil dose, and 
effect across these trials. However, a previous meta-analysis 
had indicated an association between omega-3 dose and 
effect. 
Taken together, it is perhaps easy to understand why the 
clinical community is convinced by the argument that eating 
oily fish might hold benefit (based on the population studies, 
with all their limitations), but that omega-3 capsules might not 
(based on randomized placebo-controlled trials). If oily dietary 
fish really does have improved benefit versus Omega-3 
capsules, the inference is that other components of oily fish 
are important beyond omega-3. 
Table 1. 
Double-blind intervention studies on the cardioprotective impact of 
statins and omega-3 polyunsaturated fatty acids. 
Trial title  Type of 
intervention 
Results 
GISSI-P
61
 Intervention (4 
groups: n-PUFA, 
n-PUFA and 
vitamin E, 
vitamin E, 
placebo-control) 
Treatment with n-3 
PUFA, but not vitamin E, 
significantly lowered the 
risk of death and 
cardiovascular death 
 
JELIS
62
 Intervention [2 
groups: EPA and 
statin, control 
(statin only)] 
EPA and statin lead to a 
19% relative reduction in 
major coronary events 
 
GISSI-HF
63
 Intervention (2 
groups: 
rosuvastatin, 
placebo-control) 
Statin treatment did not 
affect clinical outcomes 
in patients with chronic 
heart failure 
 
Alpha Omega
64
 Intervention (4 
groups: EPA-DHA, 
ALA, EPA-DHA 
and ALA, 
Supplementation with 
EPA–DHA or ALA did not 
significantly reduce the 
rate of major 
placebo-control)  cardiovascular events 
 
Omega
65
 Intervention (2 
groups: EPA-DHA, 
placebo-control) 
Supplementation of EPA-
DHA did not significantly 
reduce the low rates of 
cardiovascular events 
SU.FOL.OM3
66
 Intervention (3 
groups: B 
vitamins, EPA-
DHA, placebo-
control) 
Neither B vitamins nor 
EPA-DHA had any 
significant effects on 
major vascular events  
   
 
 
Mechanisms of action 
Evidence as to the mode of action of omega-3 fatty acids has 
accumulated to support a number of different aspects of 
activity (Figure 3). Brief descriptions of the evidence in support 
of the major aspects are described below: 
 
Figure 3 
  
Anti-inflammatory effects 
Omega-3 fatty acids have anti-inflammatory effects with the 
potential to influence both the atherogenic process and plaque 
stability.
69
 The most direct effect of DHA and EPA on 
inflammation is through substitution of arachidonic acid as 
substrate for cytochrome P450 and LOX-mediated metabolism 
to generate different eicosanoid products with a pro-resolving 
rather than pro-inflammatory profile.
70-72
 The science around 
the resolvins, protectins and maresins is still fairly new, but 
they mediate the resolving phase of inflammation, whereas 
the arachidonic acid-derived equivalent eicosanoids 
perpetuate inflammation. From a cardiovascular perspective, 
this could have critical consequences with respect to plaque 
stability, where unresolved inflammation is recognised to be a 
risk factor for rupture.
73-76
 Fish consumption also has a 
beneficial impact on other inflammatory markers (CRP, IL-6, 
TNF-) that have been associated with atherosclerosis,
77
 
although it is not clear whether this is linked to the eicosanoid 
effects indicated above. In addition, a recent lipidomic 
profiling study in a mouse model has indicated that feeding 
mice with a DHA-enriched diet reduces AA-derived oxylipins 
and increases those related to both EPA and DHA.
78
 In 
addition, the best correlation was found in the model between 
atherosclerosis and liver F4-isoprostanes. Although causality 
was not tested, F4-isooprostanes might represent, at the least, 
a fish oil-related marker of cardiovascular health. 
 
Inhibition of platelet aggregation 
An inhibitory effect of dietary fish oils on platelet aggregation 
was one of the first suggested modes of action of omega-3s, 
with both in vitro and dietary intervention studies supporting 
an antiplatelet effect.
79
 From a mechanistic perspective, 
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credible data suggest an antagonistic effect of DHA and EPA at 
the TXA2 receptor on platelets.
80
 However, in clinical trials fish 
oils have not shown a consistent effect on platelet aggregation 
or coagulation.
58
 
 
PAF and food-derived polar lipids 
Platelet activating factor (PAF; 1-O-alkyl-2-acetyl-sn-glycero-3-
phospho-choline) was identified in 1979,
91
 and it orchestrates 
inflammation, thrombosis and oxidation.
92
 PAF is a crucial 
mediator in the inflammatory response and it can be 
biosynthesized by various cell types upon activation, e.g. 
platelets, monocytes, macrophages, foam cells and endothelial 
cells,
93
 while the levels of PAF levels are controlled by PAF-
acetylhydrolases (PAF-AHs) which hydrolyze the sn-2 PAF 
group converting them to lyso-PAF
94
 (see part 1: remodelling 
biosynthetic pathway of PAF in Figure 4). 
 
Figure 4 
 
PAF appears to belong to a family of lipids that have different 
structures and origins but share similar bioactivity.
95
 The PAF 
family includes lipids such as oxidatively fragmented 
phosphatidyl cholines that mimic the structure of PAF to serve 
as ligands for the PAF receptor; these lipids are called “PAF-
like” lipids.
96
 The PAF-like activity of these lipids is due to a sn- 
2 residue that differs from that of PAF, which is exclusively 
derived from acetyl-CoA. As a consequence, PAF-like lipids that 
have been isolated from natural sources have totally different 
structures than PAF. The main differences are either at the sn-
2 position, where instead of the acetyl group of PAF there is 
another two or four carbon residue or at the sn-3 position on 
the glycerol backbone, where these lipids have acetyl group(s) 
on sugar moiety(ies).
95, 97
 Other PAF-like lipids exert their 
bioactivity through two vicinal hydroxyl groups in the glyceryl 
ether carbon chain in the sn-1 position, for instance 
dihydroxyl-chimyl alcohol.
100 
Similarly, PAF antagonists have a 
wide range of structures: some are analogues of PAF (e.g. 
methoxy analogue of PAF), others, like the specific PAF 
receptors antagonists BN and WEB, are structurally different 
from PAF. 
92
 
 
 
PAF is biosynthesized by two distinctive enzymatic pathways: 
a) the remodelling pathway catalyzed by lyso-PAF-acetyl-CoA 
acetyltransferase (Lyso-PAF-acetyl-transferase; Lyso-PAF-AT, 
EC 2.3.1.67 which acetylates lyso-PAF (part 1 in Fig. 4)) and b) 
the de novo pathway which is catalyzed by a specific 
dithiothreitol-insensitive CDP-choline: 1-alkyl-2-acetyl-sn-
glycerol cholinephosphotransferase (PAF-
cholinephosphotransferase; PAF-CPT, EC. 2.7.8.16) that 
converts 1-O-alkyl-2-acetyl-glycerol to PAF (part 2 in Fig. 4). 
The catabolism of PAF, to its biologically inactive form, is 
catalyzed by a PAF specific acetylhydrolase (PAF-AH, EC 
3.1.1.47) which plasma form is known as lipoprotein-
associated phospholipase A2 (Lp-PLA2) (part 3 in Figure 4).
94 
 
 
There is a wealth of evidence that it is the lipid fraction of food 
that has clear in vitro, in vivo and ex vivo biological activities 
against inflammation and the onset of atheroscelosis.
99
 In a 
recent study, it was found that the polar lipid fraction of 
gilthead sea bream (Sparus aurata) modulated PAF 
metabolism in a rabbit model of atherosclerosis by down-
regulating PAF biosynthesis (i.e. decreasing the activity of PAF-
CPT) and up-regulating PAF catabolism (i.e. increasing the 
activity of Lp-PLA2).
98
Several other studies have also found that 
polar lipids of principal food of the Mediterranean diet have 
clear anti-inflammatory activities.
100 
These studies provide 
strong evidence that the anti-inflammatory activity of the 
polar lipids is expressed by blocking the onset of inflammation 
without changing the levels of LDL-cholesterol in human 
blood,
94 
challenging the lipid hypothesis as the primary 
pathway for atherogenesis. Polar food lipids exert their 
beneficial actions by blocking the inflammation caused by PAF 
and these studies are presented in the next part of this paper.    
   
 
Anti-inflammatory activities of dietary polar lipids 
Given that PAF is recognised to be a potent pro-inflammatory 
mediator involved in the development of thrombosis and 
atherosclerosis, the presence of lipids in food that act as PAF 
antagonists is important in our quest to find alternative ways 
to inhibit atherogenesis. This inhibition is an indirect 
assessment tool for the cardioprotective properties of a 
specific food. There is a wide range of food of the 
Mediterranean diet that has been studied; these studies are 
summarised in table 2. 
 
Table 2: Platelet and inflammation studies on the cardioprotective 
impact of food polar lipids. 
 
Studied food / 
compounds 
Type of study Results 
Polar lipids of fish In vitro study using 
washed rabbits’ 
platelets  
In vivo study in 
hyperlipidemic 
rabbits 
Inhibition of platelet 
aggregation
101
  
Reduction of the 
thickness of 
atherosclerotic 
lesions
102
  
Polar lipids of fish 
fed with olive 
pomace 
In vitro study using 
washed rabbits’ 
platelets  
In vivo study in 
hyperlipidemic 
rabbits 
Inhibition of platelet 
aggregation
103
  
Reduction of the 
thickness of 
atherosclerotic 
lesions
104
  
Polar lipids of red 
and white wine 
In vitro study using 
washed rabbits’ 
platelets  
Inhibition of platelet 
aggregation
105
 
Polar lipids of olive 
oil  
In vivo study in 
hyperlipidemic 
rabbits 
Reduction of the 
thickness of 
atherosclerotic 
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lesions
106
  
Polar lipids of olive 
pomace 
In vitro study using 
washed rabbits’ 
platelets  
In vivo study in 
hyperlipidemic 
rabbits 
Inhibition of platelet 
aggregation
103 
Reduction of the 
thickness of 
atherosclerotic 
lesions
107
 
Polar lipids of dairy 
products 
In vitro study using 
washed rabbits’ 
platelets  
Inhibition of platelet 
aggregation
108, 109
 
Polar lipids of egg In vitro study using 
washed rabbits’ 
platelets  
 
Inhibition of platelet 
aggregation
110 
 
 
All these studies have been carried out with a mixture of lipid 
molecules that can potentially have either pro-aggregatory or 
inhibitory activities. These activities depend on both the 
relative ability of each molecule to aggregate platelets or 
inhibit the PAF-induced platelet aggregation and on the 
relative amount of each molecule in the mixture/food. From 
this perspective, a fraction that aggregates platelets may also 
contain lipid molecules with inhibitory properties and vice 
versa. Lipids that act as PAF agonists in fact retard the 
inflammatory activities of PAF since they compete with PAF for 
the same receptors, effectively acting as antagonists to PAF, 
hence resulting in anti-inflammatory profiles. 
 
In a mechanistic study performed by our research team, the in 
vivo effect of fish polar lipids in hypercholesterolaemic 
rabbits
102
 was linked to the in vitro effect that these lipids have 
on PAF biosynthetic and catabolic pathways.
98
 Healthy male 
New Zealand rabbits of specific weight were divided into two 
equal groups and were fed either normal rabbit food enriched 
with 1% cholesterol (atherogenic diet), or the atherogenic diet 
enriched with polar lipids of gilthead sea bream (0.06% w/w) 
for 45 days. Morphometric analysis of the arteries showed that 
atherosclerotic lesions in rabbits fed with diet enriched with 
fish polar were significantly less pronounced (76%, p<0.05) 
compared to those fed with the atherogenic diet.
102
 These 
results were associated with decreased PAF-CPT activity (see 
Figure 4) in leukocytes, as well as decreased activities of both 
PAF-CPT and Lyso PAF-AT in platelets of animals receiving 
polar lipids. In addition, it was found that both free and bound 
PAF levels increased in animals on the atherogenic diet alone, 
but decreased in those also receiving polar lipids (p<0.05). We 
suggest, therefore, that the supplementation of fish polar 
lipids to rabbits reduces the biosynthesis of PAF, which plays a 
role in limiting the atherogenic process in these animals. 
 
Following this methodology based on the pivotal role of PAF in 
atherosclerosis and the cardioprotective role of PAF-inhibitors 
derived from olive pomace, the inclusion of olive pomace in 
fish feed has been carried out for the aquaculture production 
of gilthead sea bream (Sparus aurata) and sea bass 
(Dicentrarchus labrax). Olive pomace inclusion in fish feed 
improved the nutritional value of both fish feed and fish 
possibly by enriching the marine lipid profile of gilthead sea 
bream (Sparus aurata) with specific bioactive lipid compounds 
of plant origin.
103
 The polar lipids of sea bass fed with an 
experimental diet containing olive pomace has been further 
studied. The most active fractions against platelet aggregation 
were further characterised by electrospray-mass spectrometry 
and it was elucidated that these lipid fractions contained 
various diacyl-glycerophospholipids species. The majority of 
these lipid species have either 18:0 or 18:1 fatty acids in the 
sn-1 position and either 22:6 or 20:2 fatty acids in the sn-2 
position.
111
 
Conclusions 
Atherosclerosis is a highly complex disease that requires the 
convergence of a number of pathological processes, including 
endothelial dysfunction, cholesterol peroxidation and 
inflammation. Epidemiological evidence pointing to an 
association between serum total cholesterol and CVD in some, 
but not all populations, was central to the lipid hypothesis that 
triggered research culminating in the development of statins 
and other cholesterol-lowering strategies that represent drug 
and functional food therapies for the prevention of CVD. 
However, the lipid hypothesis for CVD is not universally 
accepted and the surprisingly low CVD rate in Mediterranean 
countries, where the diet is relatively high in cholesterol, has 
never been fully explained. The same argument is the basis for 
the so-called “French-paradox”, where the disproportionately 
low incidence of CVD mortality in light of smoking and dietary 
cholesterol is often attributed to the benefits of moderate red 
wine consumption.
112, 113
 That there exist several examples of 
countries that do not support the lipid hypothesis for CVD (e.g. 
Mediterranean countries, Japan) at the very least merits a re-
evaluation of the evidence. Does dietary cholesterol really 
represent the full story, or are there critical aspects of the 
Mediterranean diet that are at least as important as 
cholesterol content in determining the mortality rate in these 
countries? 
In addressing these questions, it is important to highlight that 
not all fat is harmful: indeed, even cholesterol is not the pariah 
that it is often made out to be; after all, we synthesise it 
continuously in our livers. Add to this the recognition that fats 
from oily fish might offer some benefit, and the complex role 
of fats in CVD comes into focus. The key guiding principles 
should therefore be moderation and balance, with substantial 
inclusion of oily fish, fruit and vegetables, with a proportionate 
reduction in red meat and, importantly, sugar. While a 
reduction in dietary cholesterol might be one outcome of such 
a dietary intervention, it is not necessarily going to be the only 
contributor to any improvement in cardiovascular outcome 
that might accrue, given the potential impact on oxidative 
stress and inflammation that are also possible through other 
components of the diet. 
 
Why not just statins? 
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While there is general consensus that statins have a 
substantial impact on cardiovascular mortality, there remains a 
question as to whether this is directly linked to depression of 
plasma LDL or whether it is also driven by the so-called 
pleiotropic effects attributed to these drugs (e.g. anti-
inflammatory, antioxidant, HDL-enhancing properties). 
Furthermore, statins do not “cure” atherosclerosis, but instead 
slow the process: CVD is still a major killer despite widespread 
use of statins. In addition, there is growing evidence that, like 
all drugs, statins can induce debilitating, dose-dependent, side-
effects in a small proportion of patients and should not 
therefore be considered to be a risk-free panacea to prevent 
CVD in everybody. This is an especially important 
consideration with respect to statins as preventative therapies, 
where the balance between risk and benefit is likely to be 
much less clearly in favour of benefit. Add the healthcare cost 
to this equation and the use of statins as a preventative 
measure is unappealing.  In particular, should the increased 
risk of type 2 diabetes prove significant, there is a strong case 
that the benefits of statins might be offset by detrimental 
metabolic effects with substantial downstream health 
consequences. 
 
 
How can diet-derived lipids have a positive impact on 
atherosclerosis? 
Lipids are not universally harmful: after all, we actively 
synthesise cholesterol, fatty acids and triglycerides. Indeed, 
PUFAs from oily fish and plant sources are believed to be 
protective in CVD, although there is again some controversy as 
to whether PUFAs in isolation, or fish oils in general, are 
responsible for the benefits. The issue is further complicated 
by the results of several in vivo studies indicating that the 
development of atherosclerotic lesions independent of LDL-
cholesterol and triglycerides in the blood, but was markedly 
influenced by the anti-inflammatory action of food polar lipids 
acting as PAF inhibitors. In fact, dietary polar lipids have a 
positive impact in several diseases, apparently without severe 
side effects since they were shown to reduce side effects of 
some drugs.
16 
It could be suggested that polar lipids are more efficient 
carriers of biological information since they are highly effective 
in delivering their fatty acid residues for incorporation into the 
membranes of cells involved in different biochemical 
phenomena and diseases, e.g. atherosclerosis or development 
of cancer. 
16, 94
 We postulate that beneficial effects of polar 
lipids that are abundant in Mediterranean diets might, 
alongside dietary antioxidant and fibre content, contribute to 
an explanation of some of the anomalies associated with the 
Seven Countries Study. Furthermore, the existence of 
alternative lipids from oily fish that might have cardiovascular 
benefits beyond omega-3 PUFAs might go some way to 
explaining why eating whole fish is the preferred advice for 
prevention of CVD amongst many clinicians. Polar lipids are, 
chemically, more agile - and therefore more bioactive - than 
omega-3 PUFAs that are administered as neutral esters that 
might undergo hydrolysis during absorption in the gut. It is 
likely, therefore, that the biochemical functionality of lipids is 
partially defined by their polarity, and not only the structure of 
the free fatty acid moieties. Also, the likely synergy between 
different components of a Mediterranean diet should perhaps 
indicate that we focus less on trying to identify specific 
components that convey benefit and instead accept that the 
whole is better than the sum of its parts. 
 
Where does dietary intervention sit alongside statin therapy for 
cardiovascular disease prevention? 
Notwithstanding the controversies that still exist relating to 
mechanism, the evidence supporting cardiovascular benefits 
for both statins and Mediterranean diets is strong. The choice 
as to which approach an individual should take to reduce risk is 
as much to do with personal perspective and attitude to drug 
interventions as it is to efficacy or intolerance.  There is no 
doubt that, were we all willing and able to adopt the 
Mediterranean diet, our risk of cardiovascular disease would 
be reduced. That the populations in most developed countries 
have not adopted Mediterranean diets is testimony to how 
difficult it is to change behaviour. Equally, the fact that many 
individuals in Mediterranean countries who have always 
adhered to a healthy diet might require statins illustrates the 
point that, for some, dietary intervention is insufficient. Added 
to this, there is a small but perhaps growing population that 
would prefer to take a “natural” approach to disease 
prevention to the exclusion of therapies such as statins, while 
there is another group that are intolerant to statins for whom 
dietary intervention is more attractive because there are no 
recognised side-effects. There is clearly room, therefore, for 
both dietary and pharmaceutical approaches, either in 
isolation or in combination, to reducing cardiovascular risk – 
the decision as to which is best is as much a reflection of an 
individual’s view of disease self-management as it is of the 
evidence of efficacy of the two approaches.  
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